Stocks · News reference

Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48

Aug 19, 2026, 1:46 PMBenzinga Newsdesk

Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $56 to $48.

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 19, 2026, 1:46 PM
Checked: Aug 19, 2026, 1:46 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 13, 2026, 2:50 PMBenzinga Newsdesk
Collegium Pharma shares are trading higher after the company announced a $50 million accelerated share repurchase program.
Read original at benzinga
COLL
BenzingaAug 13, 2026, 11:32 AMBenzinga Newsdesk
Collegium Pharmaceutical Announces $50M Accelerated Share Repurchase Agreement With Jefferies, With Initial Delivery Of 1,556,420 Shares; $100M To Remain Under Program
Read original at benzinga
COLL
SEC EDGARAug 13, 2026, 11:30 AMSEC EDGAR
8-K filing — COLLEGIUM PHARMACEUTICAL, INC (COLL)
Filed: 2026-08-13 AccNo: 0001104659-26-095464 Size: 190 KB Item 8.01: Other Events
Read original at edgar
COLL